1. Nothing for something: Marketing cancer drugs to physicians increases prescribing without improving mortality. (2025). Li, Jing ; Daly, Michael ; Carey, Colleen.
   In: Journal of Public Economics.
   RePEc:eee:pubeco:v:242:y:2025:i:c:s004727272500009x.

   Full description at Econpapers || Download paper

2. The incentive to treat: Physician agency and the expansion of the 340B drug pricing program. (2025). Horn, Danea.
   In: Journal of Health Economics.
   RePEc:eee:jhecon:v:101:y:2025:i:c:s0167629625000050.

   Full description at Econpapers || Download paper

1. Agha, L. ; Zeltzer, D. Drug diffusion through peer networks: The influence of industry payments. 2022 Am. Econ. J.: Econ. Policy. 14 1-33

2. Alpert, A.E. ; Evans, W.N. ; Lieber, E.M. ; Powell, D. Origins of the opioid crisis and its enduring impacts. 2019 :

3. Amaral-Garcia, S. Medical device companies and doctors: Do their interactions affect medical treatments?. 2020 :

4. American Diabetes Association, S. Standards of medical care in diabetes - 2022 abridged for primary care providers. 2022 Clin. Diabetes. 40 10-38
   Paper not yet in RePEc: Add citation now
   

5. Athey, S. ; Imbens, G. ; Pham, T. ; Wager, S. Estimating average treatment effects: Supplementary analyses and remaining challenges. 2017 Ann. Statist.. 107 278-281

6. Athey, S. ; Tibshirani, J. ; Wager, S. Generalized random forests. 2019 Ann. Statist.. 47 1148-1178
   Paper not yet in RePEc: Add citation now
   

7. Bergman, A. ; Grennan, M. ; Swanson, A. Lobbying physicians: Payments from industry and hospital procurement of medical devices. 2021 :

8. Bongaerts, B. ; Arnold, S.V. ; Charbonnel, B.H. ; Chen, H. ; Cooper, A. ; Fenici, P. ; Gomes, M. ; Ji, L. ; Khunti, K. ; Kosiborod, M. Inappropriate intensification of glucose-lowering treatment in older patients with type 2 diabetes: The global DISCOVER study. 2021 BMJ Open Diabetes Res. Care. 9 -
   Paper not yet in RePEc: Add citation now
   
9. Brennan, P.J. Banning gifts from pharma to doctors is a big step toward increasing patient trust. 2019 The Philadelphia Inquirer. -
   Paper not yet in RePEc: Add citation now
   

10. Britto, D.G.C. ; Pinotti, P. ; Sampaio, B. The effect of job loss and unemployment insurance on crime in Brazil. 2022 Econometrica. 90 1393-1423

11. Bronnenberg, B.J. ; Dubé, J.-P. ; Gentzkow, M. ; Shapiro, J.M. Do pharmacists buy bayer? Informed shoppers and the brand premium. 2015 Q. J. Econ.. 130 1669-1726

12. Carey, C. ; Lieber, E.M. ; Miller, S. Drug firms’ payments and physicians’ prescribing behavior in medicare part D. 2021 J. Public Econ.. 197 -
    Paper not yet in RePEc: Add citation now
    

13. Carrera, M. ; Goldman, D.P. ; Joyce, G. ; Sood, N. Do physicians respond to the costs and cost-sensitivity of their patients?. 2018 Am. Econ. J.: Econ. Policy. 10 113-152

14. CDC, M. Diabetes risk factors. 2021 :
    Paper not yet in RePEc: Add citation now
    

15. Chernozhukov, V. ; Chetverikov, D. ; Demirer, M. ; Duflo, E. ; Hansen, C. ; Newey, W. ; Robins, J. Double/debiased machine learning for treatment and structural parameters. 2018 Econom. J.. 21 C1-C68

16. Chernozhukov, V. ; Newey, W. ; Singh, R. Automatic debiased machine learning of causal and structural effects. 2022 Econometrica. 90 967-1027

17. Clemens, J. ; Gottlieb, J.D. Do physicians’ financial incentives affect medical treatment and patient health?. 2014 Amer. Econ. Rev.. 104 1320-1349

18. Cohen, J. Statistical Power Analysis for the Behavioral Sciences. 1988 Lawrence Erlbaum Associates, Publishers: Hillsdale, NJ
    Paper not yet in RePEc: Add citation now
    

19. Crump, R.K. ; Hotz, V.J. ; Imbens, G.W. ; Mitnik, O.A. Dealing with limited overlap in estimation of average treatment effects. 2009 Biometrika. 96 187-199

20. Cubanski, J. ; Damico, A. ; Neuman, T. Medicare part D in 2018: The latest on enrollment, premiums, and cost sharing. 2018 :
    Paper not yet in RePEc: Add citation now
    
21. Cubanski, J. ; Neuman, T. ; True, S. ; Damico, A. How much does medicare spend on insulin?. 2019 :
    Paper not yet in RePEc: Add citation now
    

22. Dafny, L. ; Ody, C. ; Schmitt, M. When discounts raise costs: The effect of copay coupons on generic utilization. 2017 Am. Econ. J.: Econ. Policy. 9 91-123

23. Datta, A. ; Dave, D. Effects of physician-directed pharmaceutical promotion on prescription behaviors: Longitudinal evidence. 2017 Health Econ.. 26 450-468

24. Deryugina, T. ; Heutel, G. ; Miller, N.H. ; Molitor, D. ; Reif, J. The mortality and medical costs of air pollution: Evidence from changes in wind direction. 2019 Amer. Econ. Rev.. 109 4178-4219

25. Draznin, B. ; Aroda, V.R. ; Bakris, G. ; Benson, G. ; Brown, F.M. ; Freeman, R. ; Green, J. ; Huang, E. ; Isaacs, D. ; Kahan, S. 9. Pharmacologic approaches to glycemic treatment: Standards of medical care in diabetes-2022. 2022 Diabetes Care. 45 S125-S143
    Paper not yet in RePEc: Add citation now
    

26. Duggan, M. ; Scott Morton, F. The effect of medicare part D on pharmaceutical prices and utilization. 2010 Amer. Econ. Rev.. 100 590-607

27. Ellis, R.P. ; McGuire, T.G. Provider behavior under prospective reimbursement. Cost sharing and supply. 1986 J. Health Econ.. 5 129-151

28. Fabbri, A. ; la Santos, A. ; Mezinska, S. ; Mulinari, S. ; Mintzes, B. Sunshine policies and murky shadows in europe: Disclosure of pharmaceutical industry payments to health professionals in nine European countries. 2018 Int. J. Health Policy Manag.. 7 504-509
    Paper not yet in RePEc: Add citation now
    
29. Fugh-Berman, A. ; Ahari, S. Following the script: How drug reps make friends and influence doctors. 2007 PLoS Med.. 4 -
    Paper not yet in RePEc: Add citation now
    
30. Ghosh, A. ; Simon, K. ; Sommers, B.D. The effect of health insurance on prescription drug use among low-income adults: Evidence from recent medicaid expansions. 2019 J. Health Econ.. 63 64-80
    Paper not yet in RePEc: Add citation now
    
31. Gorlach, I. ; Pham-Kanter, G. Brightening up: The effect of the physician payment sunshine act on existing regulation of pharmaceutical marketing. 2013 J. Law, Med. Ethics. 41 315-322
    Paper not yet in RePEc: Add citation now
    
32. Gravelle, H. ; Liu, D. ; Propper, C. ; Santos, R. Spatial competition and quality: Evidence from the English family doctor market. 2019 J. Health Econ.. 68 -
    Paper not yet in RePEc: Add citation now
    

33. Gravelle, H. ; Scott, A. ; Sivey, P. ; Yong, J. Competition, prices and quality in the market for physician consultations. 2016 J. Ind. Econ.. 64 135-169

34. Grennan, M. ; Myers, K. ; Swanson, A. ; Chatterji, A. No free lunch? Welfare analysis of firms selling through expert intermediaries. 2021 :
    Paper not yet in RePEc: Add citation now
    
35. Hams, M. ; Wilkinson, W. Vermont shows the way on physician payment sunshine act enforcement. 2013 :
    Paper not yet in RePEc: Add citation now
    

36. Iizuka, T. Experts’ agency problems: Evidence from the prescription drug market in Japan. 2007 Rand J. Econ.. 38 844-862

37. Imbens, G. The role of the propensity score in estimating dose-response functions. 2000 Biometrika. 87 706-710
    Paper not yet in RePEc: Add citation now
    
38. Imbens, G. ; Rubin, D. . 2015 Cambridge University Press:
    Paper not yet in RePEc: Add citation now
    
39. Imbens, G. ; Rubin, D. . 2015 Cambridge University Press:
    Paper not yet in RePEc: Add citation now
    
40. KFF, G. 10 Essential facts about medicare and prescription drug spending. 2019 :
    Paper not yet in RePEc: Add citation now
    
41. Kreif, N. ; DiazOrdaz, K. ; Moreno-Serra, R. ; Mirelman, A. ; Hidayat, T. ; Suhrcke, M. Estimating heterogeneous policy impacts using causal machine learning: A case study of health insurance reform in Indonesia. 2021 Health Serv. Outcomes Res. Methodol.. 1-36
    Paper not yet in RePEc: Add citation now
    
42. Lipska, K.J. ; Ross, J.S. ; Miao, Y. ; Shah, N.D. ; Lee, S.J. ; Steinman, M.A. Potential overtreatment of diabetes mellitus in older adults with tight glycemic control. 2015 JAMA Internal Med.. 175 356-362
    Paper not yet in RePEc: Add citation now
    

43. List, J. ; Azeem, S. ; Yang, X. Multiple hypothesis testing in experimental economics. 2019 Exp. Econ.. 22 773-793

44. Lu, F. Insurance coverage and agency problems in doctor prescriptions: Evidence from a field experiment in China. 2014 J. Dev. Econ.. 106 156-167

45. Lundin, D. Moral hazard in physician prescription behavior. 2000 J. Health Econ.. 19 639-662

46. Maciejewski, M.L. ; Mi, X. ; Sussman, J. ; Greiner, M. ; Curtis, L.H. ; Ng, J. ; Haffer, S.C. ; Kerr, E.A. Overtreatment and deintensification of diabetic therapy among medicare beneficiaries. 2018 J. Gen. Intern. Med.. 33 34-41
    Paper not yet in RePEc: Add citation now
    

47. Méndez, S.J. ; Scott, A. ; Zhang, Y. Gender differences in physician decisions to adopt new prescription drugs. 2021 Soc. Sci. Med.. 277 -

48. Nie, X. ; Wager, S. Quasi-oracle estimation of heterogeneous treatment effects. 2021 Biometrika. 108 299-319

49. Oster, E. Unobservable selection and coefficient stability: Theory and evidence. 2019 J. Bus. Econom. Statist.. 37 187-204

50. Ponssen, H.H. ; Elte, J.W.F. ; Lehert, P. ; Schouten, J.P. ; Bets, D. Combined metformin and insulin therapy for patients with type 2 diabetes mellitus. 2000 Clin. Therapeutics. 22 709-718
    Paper not yet in RePEc: Add citation now
    
51. Reuters, H.H. Drugmakers pushed aggressive diabetes therapy. Patients paid the price. 2021 Reuters Ser.: Out Control. America’s Losing Battle Against Diabetes. -
    Paper not yet in RePEc: Add citation now
    

52. Robinson, P. Root-n-consistent semiparametric regression. 1988 Econometrica. 56 931-954

53. Rosenbaum, P. ; Rubin, D. The role of the propensity score in observational studies for causal effects. 1983 Biometrika. 70 41-55
    Paper not yet in RePEc: Add citation now
    
54. Stasinopoulos, J. ; Wood, S.J. ; Bell, J.S. ; Manski-Nankervis, J.-A. ; Hogan, M. ; Sluggett, J.K. Potential overtreatment and undertreatment of type 2 diabetes mellitus in long-term care facilities: A systematic review. 2021 J. Am. Med. Directors Assoc.. 22 1889-1897
    Paper not yet in RePEc: Add citation now
    
55. Sullivan, T. California senate passes ban on “gifts” to physicians. 2018 Policy and Medicine. -
    Paper not yet in RePEc: Add citation now
    
56. Tamblyn, R. ; McLeod, P. ; Hanley, J.A. ; Girard, N. ; Hurley, J. Physician and practice characteristics associated with the early utilization of new prescription drugs. 2003 Med. Care. 895-908
    Paper not yet in RePEc: Add citation now
    
57. Tibshirani, J. ; Athey, S. ; Wager, S. ; Friedberg, R. ; Miner, L. ; Wright, M. grf: Generalized Random Forests. 2022 R package version 2.2.0. -
    Paper not yet in RePEc: Add citation now
    

58. Valente, M. Policy evaluation of waste pricing programs using heterogeneous causal effect estimation. 2023 J. Environ. Econ. Manag.. 117 -

59. Wager, S. ; Athey, S. Estimating treatment effects with causal forests: An application. 2019 Observ. Stud.. 5 37-51
    Paper not yet in RePEc: Add citation now
    

60. Wager, S. ; Athey, S. Estimation and inference of heterogeneous treatment effects using random forests. 2018 J. Amer. Statist. Assoc.. 113 1228-1242

61. Yala, S.M. ; Duru, O.K. ; Ettner, S.L. ; Turk, N. ; Mangione, C.M. ; Brown, A.F. Patterns of prescription drug expenditures and medication adherence among medicare part D beneficiaries with and without the low-income supplement. 2014 BMC Health Serv. Res.. 14 14-665
    Paper not yet in RePEc: Add citation now
    
62. Zhang, Y. ; Méndez, S.J. ; Scott, A. Factors affecting general practitioners’ decisions to adopt new prescription drugs–cohort analyses using Australian longitudinal physician survey data. 2019 BMC Health Serv. Res.. 19 1-12
    Paper not yet in RePEc: Add citation now
    
63. Zhou, X. ; Shrestha, S. ; Shao, H. ; Zhang, P. Factors contributing to the rising national cost of glucose-lowering medicines for diabetes during 2005–2007 and 2015–2017. 2020 Diabetes Care. 43 2396-2402
    Paper not yet in RePEc: Add citation now
    

1. Nothing for something: Marketing cancer drugs to physicians increases prescribing without improving mortality. (2025). Li, Jing ; Daly, Michael ; Carey, Colleen.
   In: Journal of Public Economics.
   RePEc:eee:pubeco:v:242:y:2025:i:c:s004727272500009x.

   Full description at Econpapers || Download paper

2. Why higher copayments for opioids did not reduce use among Medicare beneficiaries. (2024). Kaestner, Robert ; Joyce, Geoffrey ; Zhou, BO.
   In: Health Economics.
   RePEc:wly:hlthec:v:33:y:2024:i:3:p:466-481.

   Full description at Econpapers || Download paper

3. Thick Market Externalities and the Persistence of the Opioid Epidemic. (2024). Cutler, David ; Donahoe, Travis J.
   In: NBER Working Papers.
   RePEc:nbr:nberwo:32055.

   Full description at Econpapers || Download paper

4. The cost of influence: How gifts to physicians shape prescriptions and drug costs. (2024). Valente, Marica ; Newham, Melissa.
   In: Journal of Health Economics.
   RePEc:eee:jhecon:v:95:y:2024:i:c:s0167629624000328.

   Full description at Econpapers || Download paper

5. The Political Economy of a “Miracle Cure”: The Case of Nebulized Ibuprofen and its Diffusion in Argentina. (2023). Di Tella, Rafael ; Calonico, Sebastian ; Lopez, Juan Cruz.
   In: NBER Working Papers.
   RePEc:nbr:nberwo:31781.

   Full description at Econpapers || Download paper

6. Health Crisis and Housing Market Effects - Evidence from the U.S. Opioid Epidemic. (2023). Dlima, Walter ; Thibodeau, Mark.
   In: The Journal of Real Estate Finance and Economics.
   RePEc:kap:jrefec:v:67:y:2023:i:4:d:10.1007_s11146-021-09884-8.

   Full description at Econpapers || Download paper

7. The Cost of Influence:How Gifts to Physicians Shape Prescriptions and Drug Costs. (2023). Valente, Marica ; Newham, Melissa.
   In: Working Papers.
   RePEc:inn:wpaper:2023-03.

   Full description at Econpapers || Download paper

8. The Role of Information in Pharmaceutical Advertising: Theory and Evidence. (2023). Marquardt, Kelli ; Ryan, Conor.
   In: Working Paper Series.
   RePEc:fip:fedhwp:97420.

   Full description at Econpapers || Download paper

9. The largest insurance program in history: Saving one million lives per year in China. (2023). Yi, Junjian ; Lin, Mengyun ; Gruber, Jonathan.
   In: Journal of Public Economics.
   RePEc:eee:pubeco:v:226:y:2023:i:c:s0047272723001810.

   Full description at Econpapers || Download paper

10. Third-Country Effects of U.S. Immigration Policy. (2023). Guo, Xing ; Brinatti, Agostina.
    In: Staff Working Papers.
    RePEc:bca:bocawp:23-60.

    Full description at Econpapers || Download paper

11. The Cost of Influence: How Gifts to Physicians Shape Prescriptions and Drug Costs. (2023). Valente, Marica ; Newham, Melissa.
    In: Papers.
    RePEc:arx:papers:2203.01778.

    Full description at Econpapers || Download paper

12. Prescription Limiting Laws Effects on Opioid Misuse in the United States. (2023). Chowdhury, Sulin.
    In: 2024 Annual Meeting, July 28-30, New Orleans, LA.
    RePEc:ags:aaea22:335457.

    Full description at Econpapers || Download paper

13. Medical Device Companies and Doctors: Do their interactions affect medical treatments?. (2022). Amaral-Garcia, S.
    In: Health, Econometrics and Data Group (HEDG) Working Papers.
    RePEc:yor:hectdg:22/10.

    Full description at Econpapers || Download paper

14. Demographic and Geographic Variation in Fatal Drug Overdoses in the United States, 1999€“2020. (2022). Monnat, Shannon M.
    In: The ANNALS of the American Academy of Political and Social Science.
    RePEc:sae:anname:v:703:y:2022:i:1:p:50-78.

    Full description at Econpapers || Download paper

15. Behavioral Responses to Supply-Side Drug Policy During the Opioid Epidemic. (2022). Liebert, Helge ; Sherry, Tisamarie B ; Balestra, Simone ; Maestas, Nicole.
    In: IZA Discussion Papers.
    RePEc:iza:izadps:dp15221.

    Full description at Econpapers || Download paper

16. Choices and Implications when Measuring the Local Supply of Prescription Opioids. (2022). Cho, David ; Montes, Joshua ; Mezza, Alvaro.
    In: Finance and Economics Discussion Series.
    RePEc:fip:fedgfe:2022-78.

    Full description at Econpapers || Download paper

17. Information shocks and pharmaceutical firms’ marketing efforts: Evidence from the Chantix black box warning removal. (2022). Skira, Meghan ; Lawler, Emily C.
    In: Journal of Health Economics.
    RePEc:eee:jhecon:v:81:y:2022:i:c:s0167629621001429.

    Full description at Econpapers || Download paper

18. Mortality during resource booms and busts. (2022). Hill, Elaine ; Boslett, Andrew.
    In: Journal of Environmental Economics and Management.
    RePEc:eee:jeeman:v:115:y:2022:i:c:s0095069622000614.

    Full description at Econpapers || Download paper

19. Behavioral Responses to Supply-Side Drug Policy During the Opioid Epidemic. (2022). Liebert, Helge ; Sherry, Tisamarie B ; Balestra, Simone ; Maestas, Nicole.
    In: CESifo Working Paper Series.
    RePEc:ces:ceswps:_9704.

    Full description at Econpapers || Download paper

20. The effect of medical cannabis laws on pharmaceutical marketing to physicians. (2021). Smith, Rhet ; Lebesmuehlbacher, Thomas.
    In: Health Economics.
    RePEc:wly:hlthec:v:30:y:2021:i:10:p:2409-2436.

    Full description at Econpapers || Download paper

21. The Opioid Epidemic: Causes and Consequences. (2021). Barone, Victoria ; Cabrales, Carolina Arteaga.
    In: Working Papers.
    RePEc:tor:tecipa:tecipa-698.

    Full description at Econpapers || Download paper

22. Behavioral Responses to Supply-Side Drug Policy During the Opioid Epidemic. (2021). Liebert, Helge ; Sherry, Tisamarie B ; Balestra, Simone ; Maestas, Nicole.
    In: NBER Working Papers.
    RePEc:nbr:nberwo:29596.

    Full description at Econpapers || Download paper

23. Labor Market Effects of the Oxycodone-Heroin Epidemic. (2021). Garcia, Daniel ; Cho, David ; Weingarden, Alison E.
    In: Finance and Economics Discussion Series.
    RePEc:fip:fedgfe:2021-25.

    Full description at Econpapers || Download paper

24. Drug firms’ payments and physicians’ prescribing behavior in Medicare Part D. (2021). Lieber, Ethan ; Miller, Sarah ; Carey, Colleen.
    In: Journal of Public Economics.
    RePEc:eee:pubeco:v:197:y:2021:i:c:s0047272721000384.

    Full description at Econpapers || Download paper

25. Is the rise in illicit opioids affecting labor supply and disability claiming rates?. (2021). Powell, David ; Park, Sujeong.
    In: Journal of Health Economics.
    RePEc:eee:jhecon:v:76:y:2021:i:c:s0167629621000151.

    Full description at Econpapers || Download paper

26. Can electronic prescribing mandates reduce opioid-related overdoses?. (2021). Powell, David ; Abouk, Rahi.
    In: Economics & Human Biology.
    RePEc:eee:ehbiol:v:42:y:2021:i:c:s1570677x21000241.

    Full description at Econpapers || Download paper

27. When Innovation Goes Wrong: Technological Regress and the Opioid Epidemic. (2021). Glaeser, Edward L ; Cutler, David M.
    In: Journal of Economic Perspectives.
    RePEc:aea:jecper:v:35:y:2021:i:4:p:171-96.

    Full description at Econpapers || Download paper

28. Opium Price Shocks and Prescription Opioids in the US. (2020). Nisticò, Roberto ; Giua, Ludovica ; Deiana, C.
    In: Health, Econometrics and Data Group (HEDG) Working Papers.
    RePEc:yor:hectdg:20/23.

    Full description at Econpapers || Download paper

29. The Opioid Epidemic Was Not Primarily Caused by Economic Distress But by Other Factors that Can be More Readily Addressed. (2020). Schwandt, Hannes ; Currie, Janet.
    In: Working Papers.
    RePEc:pri:econom:2020-25.

    Full description at Econpapers || Download paper

30. Burdens, Sludge, Ordeals, Red Tape, Oh My! A User’s Guide to the Study of Frictions. (2020). Mikkelsen, Kim Sass ; Madsen, Jonas Krogh ; Moynihan, Donald.
    In: SocArXiv.
    RePEc:osf:socarx:qfykb.

    Full description at Econpapers || Download paper

31. Is the Rise in Illicit Opioids Affecting Labor Supply and Disability Claiming Rates?. (2020). Powell, David ; Park, Sujeong.
    In: NBER Working Papers.
    RePEc:nbr:nberwo:27804.

    Full description at Econpapers || Download paper

32. The Opioid Epidemic Was Not Caused by Economic Distress But by Factors that Could be More Rapidly Addressed. (2020). Schwandt, Hannes ; Currie, Janet.
    In: NBER Working Papers.
    RePEc:nbr:nberwo:27544.

    Full description at Econpapers || Download paper

33. The Evolving Consequences of OxyContin Reformulation on Drug Overdoses. (2020). Powell, David ; Pacula, Rosalie.
    In: NBER Working Papers.
    RePEc:nbr:nberwo:26988.

    Full description at Econpapers || Download paper

34. Drug Firms Payments and Physicians Prescribing Behavior in Medicare Part D. (2020). Miller, Sarah ; Lieber, Ethan ; Carey, Colleen.
    In: NBER Working Papers.
    RePEc:nbr:nberwo:26751.

    Full description at Econpapers || Download paper

35. Retail Pharmacies and Drug Diversion during the Opioid Epidemic. (2020). Zhang, Xuan ; Janssen, Aljoscha.
    In: Working Paper Series.
    RePEc:hhs:iuiwop:1373.

    Full description at Econpapers || Download paper

36. The relationship of opioid prescriptions and the educational performance of children. (2020). Ozturk, Orgul ; Gordanier, John M ; Cotti, Chad D.
    In: Social Science & Medicine.
    RePEc:eee:socmed:v:265:y:2020:i:c:s0277953620306250.

    Full description at Econpapers || Download paper

37. The Economics behind the Epidemic: Afghan Opium Price and Prescription Opioids in the US. (2019). Nisticò, Roberto ; Giua, Ludovica ; Nistico, Roberto ; Deiana, Claudio.
    In: IZA Discussion Papers.
    RePEc:iza:izadps:dp12872.

    Full description at Econpapers || Download paper

Report date: 2025-09-21 03:56:55 || Missing content? Let us know